HRT Cuts Heart Disease Risk When Started Early, Study Finds
Sudden heat surges and excessive sweating arise from alterations in blood-vessel tone—periods of narrowing followed by widening—that occur as women move through the menopausal transition. These vasomotor complaints impact as many as four-fifths of women and may persist for roughly seven to ten years. Their intensity typically grows throughout perimenopause, reaching a peak shortly after menopause ends. Because these unpredictable episodes are a primary motivator for seeking hormone replacement therapy (HRT), and because HRT remains the most potent option for alleviating them, many women consider this treatment. Initiating HRT within a decade of menopause onset has been linked to an estimated 27% lower chance of developing cardiovascular disease, although the therapy is not without potential hazards.
Early-2000s clinical investigations raised alarms that HRT might raise the likelihood of heart attacks, strokes, and breast cancer. More contemporary research, however, indicates that women younger than 60 who begin hormone therapy close to menopause experience a reduced risk of heart disease compared with older counterparts who start later or avoid it entirely. To clarify how HRT used for hot-flash relief influences cardiac risk, investigators from Virginia Commonwealth University and the University of Pittsburgh examined two decades of health records from over 2,700 participants in the ongoing SWAN (Study of Women’s Health Across the Nation) cohort.
None of the enrolled women had a prior diagnosis of heart disease, and more than 750 of them commenced HRT for vasomotor symptoms during the 20-year follow-up. The extensive SWAN dataset enabled the research team to simulate a series of randomized controlled trials, which Samar El Khoudary, a senior investigator, explained to TheDoctor: “It allowed us to study clinically meaningful cardiovascular events in a population and for a length of treatment that has been challenging to study prospectively.” According to the analysis, women who received HRT exhibited a 22% reduction in major cardiovascular outcomes such as congestive heart failure, myocardial infarction, and stroke relative to non-users.
The heart-protective benefit appeared to depend on the timing of therapy. Participants who started HRT within ten years of menopause showed an estimated 27% lower risk of cardiovascular disease versus those who never used hormones. Researchers suggest that age-related deterioration of vascular health may explain this pattern; early after menopause, women are likely to have less entrenched arterial disease, whereas plaque buildup and arterial stiffening become more prevalent the longer the post-menopausal interval extends. How these evolving vascular changes interact with hormone therapy warrants additional investigation.
Outcomes also differed by race and ethnicity. Black women who began HRT in the perimenopausal or early post-menopausal stage experienced a 49% decrease in cardiovascular event risk. The investigators noted that Black women disproportionately report severe vasomotor symptoms, making the result noteworthy. “These findings highlight the need to better understand how HRT timing may influence cardiovascular outcomes across different races and ethnicities,” El Khoudary added. The analysis also observed that prolonged hormone use was associated with a heightened incidence of breast cancer.
